Prostate cancer with neuroendocrine differentiation – case report by Glück, G et al.
Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012, pp.101‐104  
 
 
 
Prostate cancer with neuroendocrine differentiation – case report 
 
Glück G*, Mihaela Mihai**, Stoica R*, Andrei R*, Sinescu I* 
*Center of Urology and Renal Transplantation, Fundeni Clinical Institute, Bucharest, Romania 
**Departament of Pathology, Fundeni Clinical Institute, Bucharest, Romania 
 
Correspondence to: Glück Gabriel, MD, PhD 
Center of Urology and Renal Transplantation, Fundeni Clinical Institute 
258, Fundeni, Bucharest, Romania, 022328 
Phone: 0722973216; E-mail: gabrielgluck@yahoo.com 
 
Received: October 1st, 2011 – Accepted: January 18th, 2012 
 
 
Abstract 
 
Rationale: About 95% of prostate cancers are adenocarcinoamas. Depending on the detection method used, neuroendocrine cells 
are found in 10% to 100% of prostate cancer specimens. 
Objective: A 64-year-old patient was diagnosed in 2006 with adenocarcinoma of the prostate, PSA 4.1 ng/ml, Gleason 6, T3b, 
positive PSA immunohistochemistry.  
Methods and results: The patient was started on hormone therapy: orchidectomy followed by flutamide 750 mg/day for three years, 
and underwent radiotherapy 6400 R. The patient was asymptomatic for three years. In 2009, the patient complained of perineal and 
rectal pain, but the PSA remained normal. In 2010, the patient underwent TUR of the prostate for acute urinary retention. 
Pathological exam revealed Gleason 8 adenocarcinoma of the prostate (different pathologist suggested Gleason 9) and foci of 
neuroendocrine cells. Immunohistochemistry detected 15-20% positivity for Cromogranin A and 10% for synaptophysin. The patient 
developed multiple liver metastases in October 2010 and underwent five cycles of etoposide, carboplatin. The patient died of liver 
failure in March 2011.  
Discussion: Regarding prevalence, neuroendocrine differentiation is the second phenotype after prostate adenocarcinoma, but still 
remains undiagnosed. It is resistant to radiation therapy and chemotherapy. Detection of the neuroendocrine differentiation is 
recommended during the clinical, biochemical, histopathological and immunohistochemical follow up of prostate cancer patients 
treated by EBRT and / or androgen deprivation.  
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Abbreviations 
CT computerized tomography; MRI magnetic rezonance imaging; NE neuroendocrine; NSAID nonsteroidal anti-inflamatory drug; 
PSA prostatic specific antigen; EAU European Association of Urology; PET Positron Emission Tomography; EBRT external beam 
radioyherapy 
Introduction 
Prostate cancer is one of the most common 
neoplasic diseases in male population. According to the 
National Cancer Institute, regarding prostate cancer, 
217,730 new cases were diagnosed and 32,050 deaths 
were registered due to prostate cancer in 2010, in the 
United States. In 2008, there were approximately 338,000 
cases in the European Union. In Romania, the incidence 
was of 32.2 (cases per 100,000 inhabitants) in the year 
2006, compared to the United States, where the incidence 
was of 95.9 for Caucasian and 127.6 for Afro-American 
population (mortality was of 3.14/100.000). 
 Case presentation  
  A 64-year-old male patient, with a single left 
kidney (history of right nephrectomy for benign condition), 
admitted in our Department, for episodes of hematuria, in 
August 2006, when, based on the clinical examination 
(rectal examination outlining a prostate of 4/4 cm with an 
endured left lobe), PSA of 4.1 ng/ml and transurethral 
prostate biopsy was diagnosed with prostate cancer - 
well-differentiated papillary tubulointerstitial 
adenocarcinoma, Gleason score was of 6 (3 +3). Fig. 1  
MRI evaluation of the prostate revealed a 
prostate tumor with left seminal vesicle invasion (T3b) and 
small pelvic lymph-nodes. Patient’s choice was surgical 
orchidectomy and antiandrogen hormonal therapy 
(flutamide 3x250 mg / day). It was locally irradiated with 
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Immunohistochemical examination from 
16.10.2006 revealed an intensely positive PSA, tubulo-
papillary and cribriform adenocarcinoma of the prostate 
(Gleason 6). The patient underwent the follow-up protocol 
according to the EAU guidelines until 2009, being 
asymptomatic, with a PSA level of 0,003 ng/ml, and with 
no postvoid residual. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From February 2009 the patient accused 
extremely intense pain in the perineum and rectum. PSA 
was of 0.003 ng/ml.  Abdominal and pelvic CT and bone 
scan were within normal limits. He completely emptied the 
bladder. Under the usual treatment with analgesics and 
NSAIDs, the pain was controlled, until February 2010. 
Digital rectal examination revealed local minimal changes 
of the prostate. Pelvic MRI showed a 4,5 cm tumor 
prostate with left extracapsular invasion, the  infiltration of 
the mezorectal fascia, of the left levator ani muscle and a 
26 mm lesion in the left femoral head.  
    The patient underwent a PET scan, which 
showed a metabolically active prostate tumor and the left 
femoral lesion. In May 2010, the patient developed urinary 
retention managed by TURP: pathological exam revealed 
adenocarcinoma of the prostate Gleason score was 8 (3 
+5), Fig. 2 
    The patient asked for a second opinion in an 
urology clinic in Turkey. Repeated MRI confirmed the 
extracapsular invasion. Ultrasound: bladder capacity of 
175 ml, prostate 55cc, postvoid residual 45 ml. Paraffin 
blocks sent for a second opinion: prostate 
adenocarcinoma, Gleason score 3 +5 (Fig. 2), 
neuroendocrine differentiation, with positivity for 
Cromogranin (Fig. 3) and synaptophysin (Fig. 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Prostate adenocarcinoma, Gleason score 6 (3+3), 
August 2006 
Fig. 2 Adenocarcinoma of the prostate Gleason 9 (4+5) 
2010 
Fig. 3 CROMOGRANIN 4x(2010) 
Fig. 4 SYNAPTOPHYSIN 10x(2010) Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
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The serum Cromogranin was of 199 micrograms 
/ ml (normal up to 98) and serotonin 5-hydroxy-indolacetic 
acid was normal. The treatment with Carboplatin and 
Etoposide was initiated. Painful symptoms were remitted. 
The patient underwent five cycles of chemotherapy, but 
developed severe neutropenia. In October 2010, the MRI 
revealed multiple masses in the liver parenchyma, varying 
between 10 and 20 mm. (Fig. 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Since November 2010 he was treated with 20 
mg of Sandostatin LAR per month, then with 
Farmarubicine. 
In February 2011, he developed an upper urinary tract 
dilatation with acute renal failure (serum creatinine 
reached 6 mg/dL and oliguria). Percutaneous left 
nephrostomy was inserted. The diuresis resumed and the 
values of creatinine reached normal levels. In March 
2011, he died from liver failure. 
Discussion  
Cellular elements of the prostate, are found on a 
base membrane of ductal and acinar secreting cells, 
basal cells, among which are the stem cells and the 
neuroendocrine cells belonging to the APUD system [1] 
(amino precursor uptake decarboxylation), which can be 
opened to the gland lumen and in contact with neural 
dendrites, or it may be closed (no communication with the 
lumen). [2-4] 
Prostate cancers are 95% adenocarcinomas. 
Depending on the technique used to detect 
neuroendocrine cells (NE) they are from 10% to 100% 
present in prostate cancers. [3,5] Histopathological forms 
are:  
- Small cell carcinomas, [6,7] - Carcinoids [8] - 
Foci of neuroendocrine neoplasic cells  in  prostatic 
adenocarcinoma.[4,6] 
This is of major importance because prostate 
cancers with neuroendocrine differentiation have a poor 
prognosis (35% survival at 2 years) compared with cases 
where there are no NE cells (97% survival at 2 years). 
[9,10] 
One of the most important things to note, is that the 
differentiation process of these neuroendocrine cells can 
appear over time. [11-13] 
The hormone dependency of the prostate 
adenocarcinoma is known since 1941. With androgen 
deprivation therapy, a regression for a period of time is 
achieved, after that the phenomenon of hormone-
resistance or hormone independence appears. [14,15] 
It seems that the NE cells are the most in this period, 
these cells displaying apoptotic activity of only 0.16%, in 
other words they are an immortal cell population in 
patients with prostate cancer. [3,16,17] They produce 
substances such as somatostatin, bombesin and 
serotonin, involved in cell growth and metastasis. Among 
the characteristic tissue and serum markers, are the 
cromogranin A, [10,18] serotonin and the synaptophysin. 
[19,20] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This patient was diagnosed with 
adenocarcinoma of the prostate in 2006, PSA 4.1 ng / ml, 
Gleason 6, T3b and positive PSA immunohistochemistry. 
The patient was irradiated up to 6400 Rad! 
Ablative hormone therapy (orchidectomy) and 
antiandrogen (flutamide 750 mg / day) was established. 
For 3 years he was asymptomatic. In 2009, he accused 
perineal and rectal pain but without PSA rise. In 2010, the 
prostate was re-resected and prostate adenocarcinoma 
Gleason score 8 and foci of neuroendocrine cells were 
Fig. 5 MRI revealed multiple formations in the 
liver parenchyma (October 2010) 
Fig. 6 Neuroendocrine-like cells in prostate cancer: 
neuroendocrine transdifferentiation of prostate 
adenocarcinoma cells. [16] Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
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diagnosed.  Serum Cromogranin A  was of 199 
micrograms/L (compared with 98- maximum admitted 
value), serotonin was 85.9 micrograms/L (compared to 
117-190 mg/L), 5-hydroxy-indolacetic acid 5.6 mg/24 
hours (N=2-9). Immunohistochemistry showed 15-20% 
positivity for Cromogranin A and 10% for synaptophysin.  
In October 2010, the patient developed multiple liver 
metastases. He underwent five courses of Carboplatin 
with etoposide, but, because of the severe adverse 
events (febrile neutropenia) the chemotherapy was 
suspended and monthly treatment with 20 mg of 
Sandostatin was instituted. He died due to liver failure in 
March 2011 
 
Conclusions  
             Neuroendocrine  differentiation  characterizes  the 
second phenotype by prevalence in comparison with the 
prostate adenocarcinoma, but remains under diagnosed. 
NE tumor cells are androgen-insensitive and have a 
mitogenic effect on adjacent tumor cells (exocrine). 
They are resistant to irradiation and 
chemotherapy. The monitoring and diagnosis of NE 
differentiation is recommended in clinical, laboratory, 
histopathological  and immunohistochemical monitoring of 
the  patients with prostate cancer treated by irradiation 
and/or androgen deprivation therapy.  
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